ReviewBiomolecules2024
The Expression of the Claudin Family of Proteins in Colorectal Cancer.
Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 18 citations in OpenAlex.
- HopRatio: Profiling single-sample transcriptomic dysregulation using stable gene-ordering relationships.iScience · 2026Article
- Article
- CLDN-2 Expression Aligns with Invasion-Associated Epithelial Remodeling in Colorectal Cancer.Cancers · 2026Article
- Antibody-drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges.Cancer chemotherapy and pharmacology · 2026Review
- Article
- Spermidine and Eugenol Modulate Tight Junction and Stemness Markers in Colorectal Cancer Spheroids.International journal of molecular sciences · 2026Article
- Screening and validation of potential molecular markers for colorectal cancer: based on bioinformatics analysis and machine learning.Clinical and experimental medicine · 2026Article
- Νovel methylation biomarkers in liquid biopsy and classifying biosignatures for the clinical management of breast cancer.Breast cancer research : BCR · 2026Article
- Claudin-1 Interacts with CD81 and Promotes the Progression of Colorectal Cancer.Oncology research · 2026Article
- Krill oil supplementation alleviates clinical symptoms and improves intestinal barrier function with transcriptomic associations to cell adhesion molecule pathways in a mouse model of spontaneous chronic colitis.Frontiers in nutrition · 2026Article
- ASCL2 contributes to clinical assessments of breast cancer and mediates tumor progression via the interaction with CLDN3.Scientific reports · 2025Article
- Novel Claudin18.2-Targeted Therapies in Gastrointestinal Tumors.ACS omega · 2025Review
- 3D collagen high-throughput screen identifies drugs that induce epithelial polarity and enhance chemotherapy response in colorectal cancer.Communications biology · 2025Article
- Evaluation of PE5 Entries on the Human Proteome Project Target List.Journal of proteome research · 2025Article
- Hsa-miR-31-3p targets CLDN8 to compromise skin barrier integrity in psoriasis.Biochemistry and biophysics reports · 2025Article
- Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger.Anti-cancer agents in medicinal chemistry · 2025Review
- Immunological landscape of colorectal cancer: tumor microenvironment, cellular players and immunotherapeutic opportunities.Frontiers in molecular biosciences · 2025Review
- Oat Beta-Glucans Modulate the Gut Microbiome, Barrier Function, and Immune Responses in an In Vivo Model of Early-Stage Colorectal Cancer.International journal of molecular sciences · 2024Article
- Engineering extracellular vesicles to transiently permeabilize the blood-brain barrier.Journal of nanobiotechnology · 2024Article
- Colon-specific controlled release of oral liposomes for enhanced chemo-immunotherapy against colorectal cancer.Acta pharmaceutica Sinica. B · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Claudins (CLDN1-CLDN24) are a family of tight junction proteins whose dysregulation has been implicated in tumorigeneses of many cancer types. In colorectal cancer (CRC), CLDN1, CLDN2, CLDN4, and CLDN18 have been shown to either be upregulated or aberrantly expressed. In the normal colon, CLDN1 and CLDN3-7 are expressed. Although a few claudins, such as CLDN6 and CLDN7, are expressed in CRC their levels are reduced compared to the normal colon. The present review outlines the expression profiles of claudin proteins in CRC and those that are potential biomarkers for prognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.